ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AGY Allergy Therapeutics Plc

2.875
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.875 2.75 3.00 2.975 2.875 2.875 320,409 08:00:06
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 59.59M -43.07M -0.0090 -3.19 136.8M

Allergy Therapeutics PLC Result of AGM (4607X)

19/11/2014 1:16pm

UK Regulatory


Allergy Therapeutics (LSE:AGY)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Allergy Therapeutics Charts.

TIDMAGY

RNS Number : 4607X

Allergy Therapeutics PLC

19 November 2014

19 November 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or the 'Company")

Result of Annual General Meeting

Allergy Therapeutics plc announces that at the Annual General Meeting held today, all the resolutions put to that meeting were duly passed.

For further information

 
 Allergy Therapeutics                   +44 (0) 1903 845 820 
 Manuel Llobet, Chief Executive 
  Officer 
 Ian Postlethwaite, Finance Director 
 
 Peel Hunt LLP                          +44 (0) 20 7418 8900 
 James Steel 
 Clare Terlouw 
 
 FTI Consulting                         +44 (0) 20 3727 1000 
 Simon Conway 
 Victoria Foster Mitchell 
 

Note to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination.Ithas a growing business achieving revenue in thelast financial year of GBP42 million mainly in Europe through its own sales and

marketing infrastructure and further afield through distributors.The Company is expanding its infrastructure into the Emerging markets.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGFFSFDUFLSEFF

1 Year Allergy Therapeutics Chart

1 Year Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart

Your Recent History

Delayed Upgrade Clock